These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27931968)

  • 61. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer.
    Katz MH; Landry J; Kindler HL
    Am Soc Clin Oncol Educ Book; 2014; ():e157-64. PubMed ID: 24857097
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?
    Brunner TB
    Curr Oncol Rep; 2013 Apr; 15(2):162-9. PubMed ID: 23325567
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer.
    Reilley MJ; Shroff R; Varadhachary GR
    Indian J Surg; 2015 Oct; 77(5):403-8. PubMed ID: 26722204
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy.
    Evans DB; George B; Tsai S
    Ann Surg Oncol; 2015 Oct; 22(11):3409-13. PubMed ID: 26122369
    [No Abstract]   [Full Text] [Related]  

  • 66. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort.
    Uzunoglu FG; Welte MN; Gavazzi F; Maggino L; Perinel J; Salvia R; Janot M; Reeh M; Perez D; Montorsi M; Zerbi A; Adham M; Uhl W; Bassi C; Izbicki JR; Malleo G; Bockhorn M
    Eur J Surg Oncol; 2019 May; 45(5):793-799. PubMed ID: 30585172
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer.
    Talamonti MS
    Cancer Treat Res; 2016; 168():59-75. PubMed ID: 29206020
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
    Goff SL; Chabot JA
    Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results.
    Chua TC; Saxena A
    Surg Oncol; 2011 Dec; 20(4):e161-8. PubMed ID: 21704510
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer].
    Zhang X; Ma YS; Tian XD; Yang YM
    Zhonghua Wai Ke Za Zhi; 2023 Jul; 61(7):546-549. PubMed ID: 37402681
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer.
    Okada KI; Kawai M; Hirono S; Tanioka K; Miyazawa M; Kitahata Y; Kobayasi R; Ueno M; Hayami S; Yamaue H
    Anticancer Res; 2020 Jul; 40(7):4033-4040. PubMed ID: 32620649
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis.
    D'Angelo F; Antolino L; Farcomeni A; Sirimarco D; Kazemi Nava A; De Siena M; Petrucciani N; Nigri G; Valabrega S; Aurello P; Ramacciato G
    Med Oncol; 2017 May; 34(5):85. PubMed ID: 28391577
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress.
    Wu HY; Li JW; Li JZ; Zhai QL; Ye JY; Zheng SY; Fang K
    World J Gastrointest Surg; 2023 Feb; 15(2):142-162. PubMed ID: 36896309
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Borderline resectable pancreatic cancer. Challenges and controversies.
    Sabater L; Muñoz E; Roselló S; Dorcaratto D; Garcés-Albir M; Huerta M; Roda D; Gómez-Mateo MC; Ferrández-Izquierdo A; Darder A; Cervantes A
    Cancer Treat Rev; 2018 Jul; 68():124-135. PubMed ID: 29957372
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer.
    Okada K; Uemura K; Kondo N; Sumiyoshi T; Nakagawa N; Seo S; Otsuka H; Urabe K; Murakami Y; Takahashi S
    Langenbecks Arch Surg; 2021 May; 406(3):679-689. PubMed ID: 33159546
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Top Pancreatic Tumor Articles from 2021 to Inform Your Cancer Patients.
    Hogg ME; Melstrom LG
    Ann Surg Oncol; 2023 Jun; 30(6):3437-3443. PubMed ID: 36917337
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pictorial review of vascular involvement and complex vascular reconstructions in borderline to minimally advanced pancreatic malignancies.
    Ly DL; Thipphavong S; Sreeharsha B
    Abdom Radiol (NY); 2017 Nov; 42(11):2675-2685. PubMed ID: 28523415
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management of borderline resectable pancreatic cancer.
    Mahipal A; Frakes J; Hoffe S; Kim R
    World J Gastrointest Oncol; 2015 Oct; 7(10):241-9. PubMed ID: 26483878
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Borderline resectable pancreatic cancer-At the crossroads of precision medicine.
    Katz MHG; Varadhachary GR
    Cancer; 2019 May; 125(10):1584-1587. PubMed ID: 30673119
    [No Abstract]   [Full Text] [Related]  

  • 80. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.
    Pijnappel EN; Suurmeijer JA; Koerkamp BG; Kos M; Siveke JT; Salvia R; Ghaneh P; van Eijck CHJ; van Etten-Jamaludin FS; Abrams R; Brasiuniene B; Büchler MW; Casadei R; van Laethem JL; Berlin J; Boku N; Conroy T; Golcher H; Sinn M; Neoptolemos JP; van Tienhoven G; Besselink MG; Wilmink JW; van Laarhoven HWM
    JAMA Oncol; 2022 Jun; 8(6):929-937. PubMed ID: 35446336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.